Iván González: A comprehensive review of immune system adverse events due to cancer immunotherapy
Iván González, Medical Oncologist at Comprehensive Oncology Center of the Hospital Ángeles Puebla, shared on X/Twitter:
“A comprehensive review of immune system adverse events due to cancer immunotherapy explored the complex pathogenic mechanisms and clinical manifestations. ICIs have revolutionized cancer treatment by boosting the anti-tumor immune response. However, this immune stimulation can trigger autoimmune responses, known as immune-related adverse events (IRAE).
This review addresses the loss of self-tolerance due to ICIs, especially CTLA4 and PD1/PD-L1 inhibitors, and their role in immune modulation that may lead to evasion of self-tolerance checkpoints.
- Importantly, while most ICI-induced toxicities are mild and manageable, less than 10% can be severe and require urgent medical attention.
- SARIs can affect a wide range of organs, with neurological, cardiovascular, hematological, rheumatic, cutaneous, and gastrointestinal manifestations among the most common.
- Diagnosing SARIs can be challenging due to the non-specificity of their signs and symptoms, as well as their overlap with primary autoimmune disorders. Therefore, a thorough understanding of the pathophysiology and clinical similarities is required to make an accurate differential diagnosis.
Given the increasing use of ICI in cancer treatment, there is a need for more clinical research and education for both clinicians and patients about the risks and management of IRAEs.”
Proceed to the article.
Source: Iván González/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023